methyl 2-(3,5-bis(trifluoromethyl)phenyl)-2-hydroxyacetate | 875443-85-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: methyl 2-(3,5-bis(trifluoromethyl)phenyl)-2-hydroxyacetate
• 英文别名: methyl [3,5-bis(trifluoromethyl)phenyl](hydroxy)acetate；Methyl [3,5-bis(trifluoromethyl)phenyl](hydroxy)acetate；methyl 2-[3,5-bis(trifluoromethyl)phenyl]-2-hydroxyacetate
• CAS: 875443-85-9
• 化学式: C₁₁H₈F₆O₃
• 分子量: 302.173
• InChiKey: MDKXYOBXGMDVNT-UHFFFAOYSA-N

物化性质

• 沸点：
  237.2±35.0 °C(Predicted)
• 密度：
  1.456±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  9

反应信息

• 作为反应物：
  描述：

  methyl 2-(3,5-bis(trifluoromethyl)phenyl)-2-hydroxyacetate 在 lithium aluminium tetrahydride 、 四溴化碳 、 三苯基膦 作用下， 以 乙醚 、 二氯甲烷 为溶剂， 反应 8.0h， 生成 2-[3,5-bis(trifluoromethyl)phenyl]-2-({[5'-isopropyl-2'-methoxy-4-(trifluoromethyl)biphenyl-2-yl]methyl}amino)ethanol
  参考文献：
  名称：

  Discovery of Substituted Biphenyl Oxazolidinone Inhibitors of Cholesteryl Ester Transfer Protein

  摘要：

  Recently, there has been a strong interest in the ability to increase levels of high density lipoprotein-cholesterol (HDL-C). This interest stems from the hypothesis that such an elevation in HDL-C will decrease the likelihood of cardiovascular disease. Inhibition of cholesteryl ester transfer protein (CETP) has been shown to elevate HDL-C levels in human subjects. This letter describes the discovery of a novel and potent (<100 nM IC(50) for the inhibition of CE transfer) CETP inhibitor scaffold containing an oxazolidinone core.

  DOI：

  10.1021/ml100309n
• 作为产物：
  描述：

  3,5-双三氟甲基苯甲醛 在 盐酸 、 水 、 对甲苯磺酸 、 sodium hydrogensulfite 作用下， 以 1,4-二氧六环 、 乙醚 、 甲苯 为溶剂， 反应 10.0h， 生成 methyl 2-(3,5-bis(trifluoromethyl)phenyl)-2-hydroxyacetate
  参考文献：
  名称：

  脂肪酶PS-30催化的立体选择性酰化反应对扁桃酸酯的动力学拆分

  摘要：

  通过使用脂肪酶PS-30作为催化剂，已通过立体选择性酰化反应实现了一系列外消旋扁桃酸酯的动力学拆分。动力学对映体比率（E）的值达到197.5。简要讨论了取代基的作用。

  DOI：

  10.1016/j.tetlet.2014.02.095

文献信息

• [EN] 1,2,4-SUBSTITUERTE 1,2,3,4-TETRAHYDRO-AND 1,2 DIHYDRO-QUINOLINE AND 1,2,3,4-TETRAHYDRO-QUINOXALINE DERIVATIVES AS CETP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROSIS AND OBESITY<br/>[FR] DERIVES DE 1,2,3,4-TETRAHYDRO- ET 1,2 DIHYDRO-QUINOLEINE ET 1,2,3,4-TETRAHYDRO-QUINOXALINE 1,2,4-SUBSTITUES, UTILES COMME INHIBITEURS DE CETP POUR LE TRAITEMENT DE L'ATHEROSCLEROSE ET DE L'OBESITE
  申请人：PFIZER PROD INC

  公开号：WO2004085401A1

  公开（公告）日：2004-10-07

  Quinoline and quinoxaline compounds of formula I and III wherein the subtituent are as defined in claims 1 and 15, pharmaceutical compositions containing such compounds and the use of such compounds to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and/or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases in some mammals, including humans.

  喹啉和喹啉并喹啉化合物的公式I和III，其中取代基如权利要求1和15中所定义的，含有这种化合物的药物组合物以及使用这种化合物来提高某些血浆脂质水平，包括高密度脂蛋白胆固醇，并降低其他一些血浆脂质水平，如LDL胆固醇和甘油三酯，并因此治疗由HDL胆固醇水平低和/或LDL胆固醇和甘油三酯水平高加重的疾病，如动脉粥样硬化和心血管疾病在某些哺乳动物中，包括人类。
• [EN] INDOLINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF ARTERIOSCLEROSIS<br/>[FR] COMPOSES A BASE D'INDOLINE ET LEUR UTILISATION DANS LE TRAITEMENT DE L'ARTERIOSCLEROSE
  申请人：PFIZER PROD INC

  公开号：WO2006032987A1

  公开（公告）日：2006-03-30

  Indoline compounds, pharmaceutical compositions containing such compounds and the use of such compounds to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and/or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases in some mammals, including humans.

  吲哚啉化合物，含有这种化合物的药物组合物，以及使用这种化合物来提高某些血浆脂质水平，包括高密度脂蛋白胆固醇，并降低其他一些血浆脂质水平，如低密度脂蛋白胆固醇和甘油三酯，并据此治疗由高密度脂蛋白胆固醇水平低和/或低密度脂蛋白胆固醇和甘油三酯水平高加重的疾病，如动脉粥样硬化和心血管疾病在某些哺乳动物中，包括人类。
• [EN] CETP INHIBITORS<br/>[FR] INHIBITEURS DE LA CETP
  申请人：MERCK & CO INC

  公开号：WO2006014357A1

  公开（公告）日：2006-02-09

  Compounds having the structures of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis: In the compounds of Formula I, B or R2 is a phenyl group which has an ortho aryl, heterocyclic, benzoheterocyclic or benzocycloalky substituent, and one other position on the 5-membered ring has an aromatic, heterocyclic, cycloalkyl, benzoheterocyclic or benzocycloalky substituent connected directly to the ring or attached to the ring through a -CH2-.

  具有公式I结构的化合物，包括这些化合物的药用盐，是CETP抑制剂，可用于提高HDL-胆固醇，降低LDL-胆固醇，并用于治疗或预防动脉粥样硬化：在公式I的化合物中，B或R2是具有邻位芳基、杂环、苯并杂环或苯环烷基取代基的苯基，而5-成员环的另一个位置具有直接连接到环或通过-CH2-连接到环的芳基、杂环、环烷基、苯并杂环或苯环烷基取代基。
• Ru-MACHO-Catalyzed Highly Chemoselective Hydrogenation of α-Keto Esters to 1,2-Diols or α-Hydroxy Esters
  作者：Weijun Tang、Jianliang Xiao、Shaochan Gao、Minghui Zhang、Chao Wang

  DOI：10.1055/s-0035-1561971

  日期：——

  catalyst has been shown to be highly effective for the hydrogenation of a wide range of α-keto esters, affording either diols or hydroxy esters depending on the choice of reaction conditions. Strong base, high temperature, and pressure favor the formation of diols whilst the opposite is true for the hydroxy esters.

  钌钳状催化剂已被证明对广泛范围的α-酮酯的氢化非常有效，根据反应条件的选择提供二醇或羟基酯。强碱、高温和压力有利于二醇的形成，而羟基酯则相反。
• Quinoline and quinoxaline compounds
  申请人：Pfizer Inc

  公开号：US20040204450A1

  公开（公告）日：2004-10-14

  Quinoline and quinoxaline compounds, pharmaceutical compositions containing such compounds and the use of such compounds to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and/or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases in some mammals, including humans.

  喹啉和喹喔啉化合物，含有此类化合物的药物组合物以及使用此类化合物提高某些血浆脂质水平，包括高密度脂蛋白胆固醇，并降低某些其他血浆脂质水平，如低密度脂蛋白胆固醇和三酰甘油，从而治疗低密度脂蛋白胆固醇水平过低和/或高密度脂蛋白胆固醇和三酰甘油水平过高加重的疾病，如动脉粥样硬化和某些哺乳动物（包括人类）的心血管疾病。